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ABSTRACT 
________________________________________________________________ 
EAE is induced to susceptible mice using linear peptides of myelin proteins of the 
central nervous system. Specific peptide motifs within the peptide-binding groove of the 
MHC peptide-complex determines the affinity of the peptide in each animal and the 
consequent T-cell receptor recognition and activation of the cell. Altered peptide ligand 
(APL) vaccination is a novel approach based on an effort to induce T-cell tolerance or 
alter cytokine profile from pro-inflammatory to anti-inflammatory. In the present study we 
synthesized the MOG35-55 peptide and altered its 3-dimensional conformation to make it 
a cyclic one (c-MOG35-55). EAE was induced in C57BL/6 mice and pathology was 
studied on acute and chronic phase of the disease. Our data indicates that c-MOG35-55 
peptide alone induces a mild transient acute phase without chronic axonopathy. 
Administration of the c-MOG35-55 peptide at a 1:1 ratio during disease induction 
significantly ameliorates clinical disease and underlying pathology, such as 
demyelination and axonopathy in the acute and chronic phases. Binding and structural 
studies revealed milder interactions between the c-MOG35-55 and mouse or human MHC 
class II alleles (H2-IAb and HLA-DR2). Collectively, we provide data supporting for the 
first time the concept that the cyclic modification of an established encephalitogenic 
peptide ameliorates the clinical outcomes and underlying pathological processes of 
EAE. Such a cyclic modification of linear peptides could provide a novel treatment 
approach for future, patient-selective, immunomodulative treatments of multiple 
sclerosis. 
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1. Introduction 
 
 Multiple sclerosis (MS) is defined as a chronic, demyelinating disease of the 
central nervous system,1 where immune cells (macrophages, T helper (h)1, Th2, Th17, 
CD8+ T cells, B cells) migrate to the site of damage (the myelin sheath) and induce 
inflammation, demyelination and neurodegenaration.1 The recognition of self myelin 
peptides by CD4+ T cells that are presented by the major histocompatibility complex 
(MHC) class II is one of the processes involved in the pathogenesis of multiple sclerosis 
(MS). Auto reactive CD4+ T cells to self antigen, myelin basic protein (MBP) residues 83-
99 (MBP83-99) in complex with HLA-DR2 (DRA, DRB1*1501) in humans is associated with 
susceptibility to MS.2-4 As a consequence, autoreactive CD4+ T cells secrete Th1 
cytokines such as, IL-1, IL-6, IFN-γ and TNF-α inducing an inflammatory mileau.5 Other 
constituents of myelin that are important in the myelination of nerves and are targets for 
autoimmune attack are, myelin oligodendrocyte glycoprotein (MOG) and proteolipid 
protein (PLP).  
 A number of studies have shown anti-MOG antibodies to be involved in the 
pathogenesis of MS.6 In addition, high T cell precursor frequencies against MOG have 
been noted patients with MS, in particular to MOG epitopes, MOG1-22, MOG34-56 and 
MOG64-96 supporting a primary role of auto-immune CD4+ T cells to MOG in disease 
development; although high levels of T cells against MOG are also noted in healthy 
individuals.7-9 Of interest, T cells isolated from HLA-DR2 positive MS patients reacted to 
MOG peptides by secretion of high IFN-γ but not by T cells from healthy individuals, 
suggesting a role of HLA-DR2 in disease.10 In fact, HLA-DR2+ and HLA-DR4+ 
(DRB1*0401) asrtocytes and microglia effectively present MOG epitopes to CD4+ T cells 
inducing mixed Th1/Th2 cytokine responses, whereas MOG epitope presentation by 
dendritic cells induce predominantly Th1 cytokines.11 Of relevance, in HLA-DR2 
transgenic mice murine MOG35-55 was noted to be strongly immunogenic and induced 
experimental autoimmune encephalomyelitis (EAE) whilst human MOG35-55 (differs by 
one amino acid of P42 instead of S42) was immunogenic but not encephalitogenic. These 
findings paved the way to studying MOG35-55 peptide as a potential pathogenic 
determinant in humans with MS.12 
 EAE is an experimental model of demyelination, inflammatory processes and 
axonopathy within the central nervous system (CNS) of susceptible animals, using the 
triggering of various CNS antigens such as MBP, PLP and MOG proteins or their 
peptides.13, 14 Due to the similarities of EAE with MS, this model is widely used to study 
pathological mechanisms as well as novel experimental treatments for the disease. EAE 
is induced to susceptible animals using linear peptides (antigens) of myelin proteins of 
the CNS. These peptides bear different antigenic properties in each animal species and 
disease is determined by the properties of the MHC class II haplotype of the animal. In 
fact, injection of C57BL/6 mice with the linear peptide of MOG35-55 (l-MOG35-55) suspended 
in complete Freund’s adjuvant (CFA) followed by 2 pertussis toxin injections, develop a 
classic self-limiting monophasic EAE with ascending flaccid paralysis within 2 weeks 
following injection and mice are usually monitored up to 50 days, depending on the 
severity of EAE symptoms.15 The interaction between the peptide, MHC class II and the T 
cell receptor (TCR) forming a trimolecular complex is the key to disease induction. Any 
modification to the antigenic peptide and any caused deviation from a tight MHC class II-
peptide-TCR complex can lead to reduced T-cell activation, T cell anergy and/or different 
cytokine profiles.16-18 Based on this concept, there have been several attempts to alter the 
trimolecular complex affinities and render autoreactive T-cells in MS and EAE inactive, 
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altered or eliminated. This approach has utilized either T-cell vaccination, T-cell receptor 
peptide vaccination, DNA vaccination or altered peptide ligand (APL) vaccination.18-26 
 In the present study we used a rather different therapeutic approach to 
ameliorate EAE in C57BL/6 mice. We synthesized the immunogenic and 
encephalitogenic MOG35-55 peptide (l-MOG35-55) and altered its 3D conformation to make 
it a cyclic one (c-MOG35-55). In this way we kept the same antigenic linear epitope of 
MOG35-55 but changed the sterotaxy of the molecule so as to reduce the affinity and 
proximity of the TCR with the MHC in the trimolecular complex. This is the first time, 
according to our knowledge, that such a chemical conformation of the linear MOG35-55 is 
reported. Using binding studies and molecular modeling of c-MOG35-55 to human (HLA-
DR2) and mouse (H2-IAb) MHC class II molecules, we also provide computational data 
on how such a cyclic conformation could affect TCR-MHC affinity. As an in vivo proof-
of-concept experimental study, we tested the possible encephalogenity of this newly 
synthesized c-MOG35-55 peptide in the C57BL/6 mice and used the peptide as a 
preventive treatment in the corresponding l-MOG35-55 model of EAE. In the induced EAE 
both clinical course and pathology were studied.  
 The development of cyclic molecules that mimic the immunomodulatory activity 
of myelin linear epitopes, while maintaining an advantage over regular peptides in 
regards to its stability, is a necessary step prior to these molecules being proposed as 
drug leads. The use of cyclic peptides instead of linear counterparts as therapeutic 
entities has a number of advantages, such as (i) stability and resistance to enzymatic 
degradation, (ii) improved receptor selectivity, resulting in an improved pharmacological 
profile, (iii) defined conformation allowing identification of active sites and, (iv) design of 
useful templates for the development of a non-peptide (mimetic) drug for oral 
administration. We previously described the rational design and synthesis of a number 
of cyclic peptides, based on a combination of conformational analysis studies and 
theoretical calculations carried out on the linear MBP peptides using 2D NOESY and 
ROESY NMR spectroscopy.17, 19-22, 27-31 
 
 
2. Results and discussion  
 
2.1. c-MOG35-55 is mildly immunogenic and ameliorates l-MOG35-55 (control) EAE 
 
 In order to test the in vivo immunogenic effects of c-MOG35-55 on EAE in mice, 
mice were injected with c-MOG35-55 peptide alone (immunogenicity) or in a 1:1 emulsion 
with the l-MOG35-55 peptide (preventive treatment; 1:1 c-MOG35-55:l-MOG35-55 peptide).  
 Our data indicate that c-MOG35-55 ameliorates both chronic and acute phase of 
EAE (Fig. 1). In the chronic experiments, mice developed moderate EAE with slow and 
relatively delayed disease onset (the clinical course of the chronic EAE is presented in 
Fig. 1A). No animals died from EAE in either group. The overall disease burden, as 
defined by the mean Areas Under the Curve (mAUC, Fig. 1B), for each group was 
significantly lower in group B (mAUC = 39.63 ± 7.12) compared to control group mAUC 
= 68.72 ± 11.07, p=0.036). The mean clinical score was statistically significantly 
different at days 21-28, 30-34 and 46 (p<0.05). The maximal disease burden (as 
defined by Mean Maximal Clinical Scores, MMS) was significantly lower in treated 
group as compared to controls (control MMS = 3.3 ± 0.42 and group B MMS = 2.13 ± 
0.34, p=0.043, Fig. 1C). Both groups had a similar day of disease onset (dDO), defined 
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as the first day with clinical score of “1”, (control = 17.90 ± 3.17 and group B = 21.90 ± 
3.32; Kaplan-Meier survival analysis, log rank p=0.358, Fig. 1D).  
 Experiments of the acute phase of EAE replicated the main acute clinical 
findings of chronic experiments, importantly under a more severe, more aggressive and 
faster disease background (Fig. 1E). By definition, all mice were sacrificed 5 days post 
their first clinical sign of EAE (i.e on day 16, acute phase). No animals died in either 
group, until the day of sacrifice. The burden of disease for the acute phase (mAUC, Fig. 
1F) was lower for group B (treated) compared to control (group B mAUC = 7.62 ± 2.09, 
control group mAUC = 18.56 ± 1.46, p=0.01). Treated mice had lower mean clinical 
scores from day 11 onwards (p<0.05 for day 11, p<0.01 for days 14-16). The maximal 
disease burden (MMS) was not calculated for this experiment because mice were not 
followed-up long enough to reach their maximal scores. Again, both groups had almost 
similar day of disease onset (mean dDO for control = 11.67 ± 0.49 and group B = 13.67 
± 0.84; Kaplan-Meier survival analysis, log rank p=0.073, Fig. 1G). 
 Injection with the c-MOG35-55 alone showed a mild encephalitidogenic potential 
for the peptide, that is not sustained long-term. Mice injected with c-MOG35-55 peptide 
alone developed a mild disease, with one mild acute phase and minimal residual 
chronic deficits, compared to a severe chronic EAE of control animals (p<0.01 for days 
14 onwards, Fig. 1H). The total disease burden by c-MOG35-55 was minimal in most 
mice (c-MOG35-55 mAUC = 29.45 ± 14.87, control group mAUC = 109.29 ± 17.83, 
p=0.002, Fig. 1I). Although mice developed some mild to moderate disease symptoms 
(c-MOG35-55 MMS = 1.5 ± 0.48, control group MMS = 3.30 ± 0.47, p=0.033, Fig. 1J), 
these were not sustained long-term, suggesting a long-term disease resolution with 
minimal or no residual deficits. Disease onset was statistically similar in both groups (c-
MOG35-55 and l-MOG35-55, Kaplan-Meier survival analysis log-rank test p=0.0629), 
despite the fact that c-MOG35-55 mice had a trend for delayed disease onset (Fig. 1K). 
 Taken together, the clinical data suggests that injection with c-MOG35-55 has a 
very low encephalitogenic potential. However, the addition of c-MOG35-55 in the 
immunizing emulsion of EAE (l-MOG35-55) ameliorates the overall disease burden and 
maximal clinical deficits, suggesting a preventative or immunomodulative effect for c-
MOG35-55 peptide.  
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Fig. 1. Clinical course and outcome parameters of EAE with or without c-MOG35-55. Panels (A-D) 
show the long-term (chronic) clinical course and parameters of animals co-immunized with the c-
MOG35-55 peptide (+cMOG): (A) the long-term follow-up of the disease, (B) the overall burden of 
disease (mAUC), (C) the maximal disease deficits (MMS) and (D) Kaplan-Meier survival analysis 
for the disease onset (% disease free animals). Panels (E-G) show the corresponding short-term 
(acute) clinical course and parameters of animals co-immunized with the c-MOG35-55 peptide 
(+cMOG): (E) short-term follow-up, (F) burden of the disease and (G) survival analysis for the 
disease onset. Panels (G-J) show the long-term clinical course and parameters of animals 
immunized only with the c-MOG35-55 peptide (cMOG) compared to controls (immunized with the 
l-MOG35-55): (G) the long-term follow-up of the disease, (H) the overall burden of disease, (I) the 
maximal disease deficits and (J) survival analysis for the disease onset. Control groups in all 
EAE experiments are immunized with the l-MOG35-55 peptide. * denotes p<0.05, ** p<0.01. Data 
of EAE cliical scores (A, E, G) are displayed as mean ± standard deviation (SD); horizontal lines 
in dot plots show means. 
 
2.2. Histopathological evaluation  
 
2.2.1. Co-immunization with c-MOG35-55 reduces inflammatory processes of EAE  
 Study of inflammatory processes at acute and chronic phase of EAE showed 
that c-MOG35-55 ameliorated the inflammatory processes of EAE. More specifically, 
during the acute phase, c-MOG35-55reduced the total number of infiltrating cells per mm2 
(control group 260.51 ± 19.30, group B 172.23 ± 18.91, p=0.001, Fig. 2) and the size of 
inflammatory foci (inflammatory cells per infiltration: control group 55.75 ± 3.90, group B 
37.61 ± 3.25, p<0.001). As a result, the chronic residual inflammatory burden (number 
of infiltrating cells per mm2 (control group 28.14 ±4 .67, group B 14.36 ± 3.13, p=0.015, 
Fig. 3) and the size of inflammatory foci (control group 15.76 ± 2.34, group B 7.54 ± 
1.27, p=0.002) were also ameliorated by the c-MOG35-55. 
 Taken together, these data indicate that c-MOG35-55 ameliorates the acute 
inflammatory processes within the spinal cords of the mice, which reflects to a reduced 
inflammatory burden long-term. 
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Fig. 2. (A) Demyelinating, (B) inflammatory and (C,D) axonopathic processes of control and 
+cMOG groups during the acute phase of EAE, in spinal cords. Graphs C and D show the 
axonal injury (AI) and loss (AL) as a semiquantitative distribution of severity (scales 0 to ++++ on 
the right side of graphs). Photos E and F show representative longitudinal spinal cord sections 
(under 10x objective) of a control and +cMOG co-immunized animal stained with LFB (blue: 
intact myelin, red: cell nuclei; arrows point at sites of inflammatory foci and/or demyelination). 
Note the more pronounced inflammation and demyelination of control mice. Photos G-H show 
representative longitudinal spinal cord sections (under 10x objective) of a control and +cMOG 
co-immunized animal stained with Bielschowsky and Hematoxylin (BLS+Hem) for axonopathy 
and inflammation (blue: cells bodies, dark brown: axons); inserts show magnifications of a cut 
axon in a control animal (spheroid/ovoid, insert of G) or intact axons next to inflammatory cells in 
+cMOG co-immunized animal (insert of H). *** denotes p<0.001. Data are displayed as mean ± 
standard error of the mean (SEM) 
 
 
2.2.2. Co-immunization with c-MOG35-55 reduces axonopathy and demyelination of EAE 
 Study of axonal pathology revealed a significant effect of c-MOG35-55 treatment 
on axonal injury and loss. During acute phase, co-immunization with c-MOG35-55 
resulted in reduced axonal injury (AI) and axonal loss (AL) compared to control 
(Pearson’s chi-square tests, p<0.001, Fig. 2C-D, G-H). During chronic phase, axonal 
loss was less in the mice co-immunized with c-MOG35-55, compared to control 
(Pearson’s chi-square test, p=0.001, Fig. 3D, G-H), reflecting an long-term axonal 
protection from c-MOG35-55 peptide. Active axonal injury during the chronic phase 
(presence of dystrophic or cut axons, depicted as "pearls-strings" and 
"ovoids/spheroids" morphology; inserts in Fig. 3C, G-H) was also ameliorated in mice 
co-immunized with c-MOG35-55 compared to controls, although this was marginally not 
statistically different (Pearson’s chi-square test, p=0.071).  
 Studies of demyelination (on sections stained with LFB) showed that co-
immunization with c-MOG35-55 reduced the demyelinating area during acute phase, 
compared to controls (control group = 20.73 ± 1.34 and group B = 7.99 ± 0.83, p<0.001, 
Fig. 2A, E-F). The same beneficial effect of c-MOG35-55 was also noted during the 
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chronic phase of the disease (control group = 14.92 ± 0.92 and group B = 6.77 ± 0.67, 
p<0.001) (Fig. 3A, E-F).  
 Taken together, these data indicate that c-MOG35-55 significantly reduces the 
demyelinating and axonopathic processes of EAE during the acute phase of the 
disease, resulting in better anatomical integrity of the white matter tracts of the spinal 
cord. Importantly, this beneficial effect is maintained up to the chronic phase of the 
disease and is reflected to better neurological scores for the treated group  
 
 
 
 
Fig. 3. (A) Demyelinating, (B) inflammatory and (C,D) axonopathic processes of control and 
+cMOG groups during the chronic phase of EAE, in spinal cords. Graphs C and D show the 
results of axonal injury (AI) and loss (AL) as a semiquantitative distribution of severity. Photos E 
and F show representative longitudinal spinal cord sections (under 10x objective) of a control 
and +cMOG co-immunized animal, stained with LFB (blue: intact myelin, red: cell nuclei; arrows 
point at sites of inflammatory foci and/or demyelination). Note the residual inflammation and 
pronounced demyelination of control mice with presence of vacuolation and myelin debris (blue 
staining within vacuoles or cells, insert in e). Photos G-H show representative longitudinal spinal 
cord sections (under 10x objective) of a control (G) and +cMOG co-immunized (H) mice stained 
with BLS+Hem for axonopathy and inflammation (blue: cells bodies, dark brown: axons); inserts 
show magnifications of an area with severe axonal loss and ongoing injury in a control animal 
(almost complete absence of dark brown axons with simultaneous presence of spheroids, insert 
of G) or mild axonal injury with intact axons in a +cMOG co-immunized animal (insert of H). * 
denotes p<0.05, * p<0.001. Data are displayed as mean ± standard error of the mean (SEM) 
 
 
2.3. Binding mode of l-MOG35-55 and c-MOG35-55 peptides in complex wih murine MHC 
class II (H2-IAb)  
 
 A number of studies have identified the mode of binding of l-MOG35-55 to murine 
MHC class II, H2-IAb.27, 28 It was noted that the amino acids in MOG38-51 peptide were 
important for binding to H2-IAb. Residues R41, F44, R46 and V47 constituted the major T 
cell receptor contact residues since Ala substitutions abrogated T cell responses 
without affecting the binding affinity of the peptide to H2-IAb;27 G38 and W39 act as 
minor T cell receptor binding residues. In addition, Y40 was identified to be important in 
anchoring the peptide to H2-IAb, which occupies pocket P1 of the commonly identified 
pockets of MHC complexes,27 as Ala substitution at this residue decreaed the binding 
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affinity of the peptide to H2-IAb up to 50 %. Considering this information for validation 
purposes, the l-MOG35-55 sequence was examined for its positioning to the H2-IAb using 
the IEDB server, which uses several algorithms for identifying positioning of antigens 
within MHC alleles (see materials and methods). The results showed a predicted 
higher affinity of the YRPPFSRVV sequence (MOG40-48) than the CLIP91-99 peptide that 
was used for comparison purposes as it has been co-crystallized with H2-IAb (Table 1). 
This result, being in accordance with the aforementioned experimental results, showing 
that pockets P1-P9 are more probable to be occupied by the specific MOG40-48 
sequence, was used to build the models of the l-MOG35-55 and c-MOG35-55 interaction 
with H2-IAb.  
 The 3-D complex models of l-MOG35-55-H2-IAb and c-MOG35-55-H2-IAb were 
consecutively built by amino acid replacement through homology modeling, in order to 
gain a better understanding of the elements of anchoring. The occupancy of pockets 
P1-P9 and the respective MOG40-48 sequences is shown in Fig. 4. Pockets P1-P9 are 
occupied by residues Y40RPPFSRV48 respectively in both peptides, l-MOG35-55 and c-
MOG35-55. In the case of l-MOG35-55 (Fig. 4a) Y40 occupies P1, forming electrostatic 
interactions between the hydroxyl group and E86β. P4 is occupied by P43 making 
hydrophobic interactions with F11α, V78α and a hydrogen bond with N62α. S45 
interacts with N69α in P6 and V48 is located in a hydrophobic environment of P9 
interacting with V72α and W61β.  In the case of c-MOG (Fig. 4b), cyclization does not 
seem to interfere with the occupancy of pockets P1, P4, P6 and P9 similarly to our 
previous reported in smaller length cyclic APLs.29 The topology of corresponding 
MOG40-48 residues to pockets P1, P4, P6 and P9 is the same, as the 20 length cyclic 
peptide and has adequate backbone length to dock to the MHC class II. Residues 
N53GK55-M35EV37 point towards the TCR interaction site.   
 Based on the clinical and neuropathological data (approximately 50 % better 
clinical and histological outcomes), we may assume that c-MOG35-55 (when animals are 
co-immunized with a 1:1 cyclic-linear emulsion) is antagonizing the linear peptide for 
induction of immune responses. We hypothesize that a peptide-specific antagonism (c-
MOG35-55 against l-MOG35-55) is likely responsible for the beneficial effects of c-MOG35-55 
since c-MOG35-55 confers a similar binding affinity consensus and affinity with l-MOG35-55 
to H2-IAb (Table 1). In addition, as c-MOG35-55 binds within the H2-IAb binding groove 
the TCR contact residues are different to that of l-MOG35-55, hence it could lead to T cell 
antagonism. The data of co-immunization with c-MOG35-55 have been replicated in 2 
experimental sets (acute and chronic). This increases the validity of the data, as a 
prerequisite according to ARRIVE criteria.30 
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Table 1 
Highest ranked peptides using the consensus approach for prediction of peptide binding affinity 
to the H2-IAb allele on the free epitope database and prediction resource (IEDB). Peptides are 
ranked (Rank percentage) using the consensus method.  
______________________________________________________________________ 
Peptide  Residue  SMM-align NN-align % Rank 
  positioning  predicted  predicted  
   IC50 (nM) IC50 (nM) 
 123456789    
______________________________________________________________________ 
 
MOG40-48 YRPPFSRVV 72  15.50  0.28  
(linear, cyclic) 
 
MBP87-95 YRPPFSRVV 236  79.40  1.78 
 
CLIP91-99 MRMATPLLM 2113  281  10.90 
(control) 
______________________________________________________________________ 
NN-align, an artifical neural network-based alignment algorithm for MHC class II peptide binding 
prediction; SMM-align, stabilization matrix alignment method for prediction of MHC class II 
binding affinity. 
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Fig. 4. Ribbon and surface representations of (A) l-MOG35-55 (in yellow) and (B) c-MOG35-55 (in 
orange) peptides bound to the modeled H2-IAb. Chains α and β are shown in wheat and cyan 
colors respectively. Peptide numbering is shown in bold letters. 
 
2.4. Binding studies of l-MOG35-55 and c-MOG35-55 peptides in complex with human HLA-
DR2 (DRB1*1501) 
2.4.1. Both l-MOG35-55 and c-MOG35-55 bind to HLA-DR2.  
 In order to determine the binding ability of l-MOG35-55 and c-MOG35-55 peptides to 
HLA-DR2 in vitro, competition assays were used based on a gel filtration method as 
previously published.17, 31-36 MBP83-99-AMCA-labeled peptide and immunoaffinity purified 
HLA-DR2 isolates from EBV transformed human DRB1*1501 B cell lines. As 
competitors l-MOG35-55 and c-MOG35-55 peptides were used in different concentrations, 
MBP83-99 was used as a positive control. Linear MOG35-55 bound with high affinity similar 
to that of control MBP83-99 peptide and c-MOG35-55 peptide bound with reduced binding 
capacity to HLA-DR2 but still with considerable affinity (Fig. 5) 
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Fig. 5. Binding of l-MOG35-55  and c-MOG35-55 peptides to HLA-DR2. Competition binding of 
MBP83-99 AMC-labelled peptide with 10-fold, 20-fold or 50-fold (M) excess of MBP83-99, l-
MOG35-55 or c-MOG35-55 peptides. % competition is shown on the y-axis and peptides are labeled 
on the x-axis. The experiments were done in triplicate and the results are given as mean ± 
standard error of the mean (SEM). 
 
2.4.2. c-MOG35-55 adopts a similar conformation to linear MBP83-99 
 In order to assess the data of l-MOG35-55 and c-MOG35-55 peptide binding to HLA-
DR2, MOG35-55 sequence was examined for its positioning to the HLA-DR2 using the 
IEDB server, compared to MBP83-98 sequence (Table 2). From the peptides affinity 
prediction, the optimal predicted binding sequence for l-MOG35-55 is F44SRVVHLYR52. 
What was remarkable to find is that, the resulting MOG35-55 sequence in the cyclic 
peptide, contains a highly homologous sequence to MBP83-99 due to the cyclic nature 
produced by the fused termini. Specifically, the highest scored sequence of cMOG, 
MOG[(48-55)-(35)] (brackets denote the linear sequence parts in the context of a cyclic 
peptide) V48HLYRNGK55-M35, is homologous to the MBP87-95 P1-P9 occupying residues 
V87HFFKNIVT95.37, 38 Comparing the two sequences residues  occupying pockets P1, 
P2 and P6 are identical (V, H, N respectively) and pockets P3, P4 and P5 have similar 
corresponding residues (F/L, F/Y and R/K respectively). The MOG[(48-55)-(35)] sequence 
was predicted to have similar affinity to MBP87-95 and considerably higher that MOG44-52 
in all three used algorithms.  
 To assess the binding prediction results, models of the peptides in complex with 
HLA-DR2 were generated using homology modeling. Fig. 6 depicts the crystal complex 
of HLA-DR2 with MBP83-98 and the modeled complexes with l-MOG35-55 and c-MOG35-55. 
HLA-DR2 has a highly hydrophobic P1 pocket formed by F24α, F32α, V85β and V86β, 
in which V87 of ΜΒΡ83-98 is positioned (Fig. 6a). F90 of ΜΒΡ83-98 is located in pocket P4, 
comprised of R13β, F26β, Q70β and Y78β, N92 interacts with E11α and R13β in P6 and 
T95 is located between I71α and D57β. In the case of l-MOG, F44 and V47 occupy 
hydrophobic pockets P1 and P4 respectively (Fig. 6b). H49 is positioned in P6 and R52 is 
buried deep in P9, probably forming a strong salt bridge with the D57β side chain. For 
c-MOG35-55, as mentioned before, the MOG[(48-55)-(35)] sequence that occurs after 
cyclization is highly homologous to MBP87-95 (Table 2) and was therefore expected to 
have a very similar interaction pattern (Fig. 6c). Indeed, the model complex showed the 
exact same topology for residues V48, H49 and Y51 compared to MBP87-95 V87, H88 and 
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F90 occupying pockets P1, P2 and P4 respectively. R52 in P5 looses its extended side 
chain conformation pointing to TCR, due to the cyclization steric overlap with c-MOG35-
55 backbone. Lastly, M35 occupies P9, mainly interacting with I72. The binding 
conformational data confirms that even though c-MOG35-55 is a weaker binder to its 
linear counterpart, l-MOG35-55 (due to the cyclization effects) it still has considerable 
affinity to HLA-DR2 (Fig. 5). 
 
 
Table 2  
Highest ranked peptides using the consensus approach for prediction of peptide binding affinity 
to HLA-DR2 (DRB1*1501) allele on the free epitope database and prediction resource (IEDB). 
Sequences in brackets denote the cyclic nature of the peptide. Peptides are ranked (Rank 
percentage) using the consensus method.  
_____________________________________________________________________ 
Peptide  Residue SMM-align NN-align Sturniolo % Rank 
  positioning predicted  predicted score 
  IC50 (nM) IC50 (nM) 
 123456789    
_____________________________________________________________________ 
 
MBP87-98 VHFFKNIVT 22  12.60  6  0.10  
(control) 
 
MOG[(48-55)-(35)] VHLYRNGKM 135  27.40  5.08  1.93  
(cyclic) 
 
MOG44-52 FSRVVHLYR 528  57.90  2.80  5.94  
(linear) 
____________________________________________________________________ 
NN-align, an artifical neural network-based alignment algorithm for MHC class II peptide binding 
prediction; SMM-align, stabilization matrix alignment method for prediction of MHC class II 
binding affinity; Sturniolo score, a prediction software that scans tissue-specific and promiscuous 
HLA class II peptide databases using DNA microarrays and virtual HLA class II matrices 
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Fig. 6. Ribbon and surface representations of the (A) MBP83-99 (in blue) - HLA-DR2 crystal 
structure 37 and model complexes of (B) l-MOG35-55 (in yellow) and (C) c-MOG35-55 (in orange) 
peptides bound to HLA-DR2. Chains α and β are shown in green and gray colors respectively. 
Peptide numbering is shown in bold letters. 
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3. Conclusion 
 
 Our proof-of-concept studies support our hypothesis that co-administration of a 
c-MOG35-55 peptide at a 1:1 ratio with the corresponding l-MOG35-55 peptide during the 
induction of EAE ameliorates its clinical course. This is reflected to reduced clinical 
severity of the acute phase as well as reduced overall disease burden. Such clinical 
effects result from the ameliorated inflammatory, axonopathic and demyelinating 
processes within the CNS of the treated animals. The benefit in inflammatory processes 
is maintained during both acute and chronic phases of EAE. The same is also evident 
for the demyelinating processes. Axonopathy is also significantly reduced during the 
acute phase of the disease and this results to an important white matter tract 
preservation during the chronic phase of EAE. Importantly, the conserved myelination 
and axonal integrity of spinal cord tracts in animals co-immunized with c-MOG35-55 
peptide are reflected to significantly ameliorated chronic neurological deficits in these 
animals, compared to controls.  
 Our data from the modeling and binding studies provide a further insight on such 
a beneficial effect of c-MOG35-55 on EAE. Although c-MOG35-55 binds to mouse (H2-IAb) 
and human (HLA-DR2) MHC class II molecule, it has lower affinity to its linear 
counterpart (l-MOG35-55) and to control agonist peptide MBP83-99. At the same time, the 
binding of c-MOG35-55 to HLA-DR2 results in a somewhat different amino acid contact to 
the TCR which could potentially result in TCR antagonism and thus explain part of the 
beneficial effects on EAE. Eventually, this novel peptide (c-MOG35-55) could possibly be 
conjugated to an appropriate carrier (ie. mannan, targeting antigen presenting cells) to 
result in a novel immunomodulatory treatment of human MS where l-MOG35-55 
autoimmunity plays a role in the pathogenesis of disease.19-21, 23-25 
 
4. Experimental section 
 
4.1. Solid-phase peptide synthesis of cyclic-MOG35-55 
 
 Linear protected MOG35-55 (rat, mouse) (H2N-Met35-Glu-Val-Gly-Trp-Tyr-Arg-
Ser42- Pro-Phe-Ser-Arg-Val-Val-His-Leu-Tyr-Arg-Asn-Gly-Lys55-OH) was synthesized 
on 2- chlorotrityl chloride resin (CTLR-Cl) using the Fmoc/tBu methodology (Scheme 
1). All amino acids were purchased from CBL (Patras, Greece). Peptide synthesis was 
on a 0.5 mmol scale up to the final protected analog. The use of the 2-chlorotrityl resin 
under mild conditions (DCM/TFE, 7/3) for cleaving the peptide-resin bond, allowed the 
release of high yield and purity of the protected peptide from the resin. Yield of fully 
protected peptide-resins was > 90 %. 
 Cyclization of linear protected MOG35-55 was achieved using O-benzotriazol-1-
yl-N,N,N’,N’-tetramethyluronium tetrafluoroborate (TBTU) and 1-hydroxy-7- 
azabenzotriazole, 2,4,6 collidine in DMF solution, allowing fast reactions and high yield 
cyclization products (Scheme 2). The cyclization reaction was monitored using the 
ninhydrin test, and the reaction mixture was resolved by thin-layer chromatography, 
nbutanol/acetic acid/water (4/1/1) solvent system and analytical HPLC in C4 
Nucleosil RP column 5nm packing material. The protected cyclic analog was then 
released from side chain protected groups with 90 % trifluoroacetic acid (TFA) in DCM 
solution containing 5 % Dithiothreitol/water/Anisole as scavengers. Purification of the 
final cyclic peptide analog was accomplished with the use of a Waters Delta Prep 
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HPLC chromatography system equipped with a Prep LC controller and a Waters 
2996 Photodiode array detector. Separation was achieved on Nucleosil RP-18 reverse 
phase column with a 7 μm pack material with a stepped linear gradient of acetonitrile 
in 0.1 % CF3CO2H at a flow rate of 8ml/min. Cyclic analogue, 5 mg per sample was 
injected for the collections of the fractions according to the chromatogram data. Elution 
of the peptide analogue was detected form the absorbance at 254 nm and 230 nm 
simultaneously. The fractions containing the required peptide were pooled following 
removal of CH3CN on a rotary evaporator at 40 C and lyophilized. The final cyclic 
peptide was > 98 % pure as analyzed by analytical RP-HPLC and ESI-MS (Fig. 7). 
 
 
 
Scheme 1: Schematic representation of chemical synthesis of c-MOG35-55 peptide   
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Fig. 7. (A) Analytical RP-HPLC of purified (purity > 98 %) c-MOG35-55 peptide. Column: Xbridge 
C18, 150mm×4.6 mm, 3.5µm packing (Part/N= 186003034). RT: 9.49min Conditions: gradient 
5% (B)-100% (B), in 30 min, flow rate 1 mL/min. [Eluents (a): solution TFA in H2O 0.1% (v/v), 
(b): solution TFA in AcN 0.1% (v/v)]. (B) ESI+MS of c-MOG35-55 peptide. M +2H+/2: 1282.83, M 
+3H+/3: 855.23. M +4H+/4: 642.23]. 
 
 
4.2. Animal handling 
 
 Female C57BL/6 pathogen-free mice were purchased from Hellenic Pasteur 
Institute, Athens, and housed in the animal facility of the B’ Neurological Department of  
the AHEPA University Hospital, Aristotle University Medical School in accordance with 
the National Institute of Health guidelines. Mice were fed a regular diet and given water 
without antibiotics. 
 
4.2.1. EAE induction and evaluation of clinical disease 
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 MOG EAE was induced as we previously described.39, 40 Briefly, female C57BL/6 
10 weeks-old mice, were divided into different groups depending on the peptides used. 
Control groups in all experiments were injected with 300 μg of linear-MOG35-55 or c-
MOG35-55 peptides (mouse, rat) (synthesized by the group of Prof. Matsoukas). Mice 
were also immunized using a 1:1 mixture of the linear MOG35–55 peptide together with 
cyclic MOG35-55 (c-MOG35-55). All groups were injected subcutaneously (sc) at the left 
para-lumbar region of emulsions composed of the specific peptide mixture diluted in 
100 μl filtered phosphate buffered saline (PBS) and emulsified with 100 μl complete 
Freund's adjuvant (CFA) with 4 mg/ml Mycobacterium tuberculosis H37RA, to a total 
injected volume of 200μl (day 0). Additionally, on day of induction (day 0), all groups 
were also given intraperitoneally (ip) 400 ng of pertussis toxin (Sigma) diluted in 0.5 ml 
of filtered PBS. On day 2, a further 200 ng of pertussis toxin was injected ip. A second 
injection of the emulsified peptides, was also delivered 7 days later into the right para-
lumbar region. 
 Three experiments were conducted using exactly the same experimental 
procedures: (i) chronic EAE, mice were sacrificed at day 46 post disease induction; (ii) 
acute EAE, mice were sacrificed at day 17 post disease induction, and, (iii) comparison 
between the immunogenic properties of c-MOG35-55 versus linear MOG35-55. All mice 
were examined daily and evaluated for body weight changes and clinical signs of 
disease. The clinical status of the mice was graded as follows: 0, without clinical 
disease; 1, flail tail; 2, tail paralysis; 3, hind limb weakness sufficient to impair righting; 
4, paraplegia; 5, paraplegia with forelimb paresis or plegia; 6, death from EAE. 
 
4.3. Histopathology  
 
 On acute (day 17) and chronic (day 46) phase of EAE, mice were subjected to 
transcardial perfusion with 4 % paraformaldehyde in PBS (pH 7.2, ice cold). Brains and 
spinal cords were removed, post-fixed in the same fixative for approximately 20 hours, 
routinely processed for paraffin embedding and sectioned at 6 μm. Sections from mice 
of acute and chronic phases of the disease, were then stained using the following 
methods: (i) a modified Bielschowsky silver (BLS) impregnation staining method 
combined with haematoxylin (Hem) (BLS+Hem), for the simultaneous evaluation of 
axonal injury, axonal loss and inflammatory processes in EAE as previously 
described;41 (ii) Luxol fast blue (LFB) staining counterstained with Nuclear fast Red for 
the detection of demyelinating areas within the CNS of mice, using routine 
histopathological protocols. 
 Pathological evaluation was performed under a light microscope (Olympus 
Axioplan-2) by two blinded investigators and photos were taken using a CCD camera 
(Nikon). Five randomly selected longitudinal sections per tissue (brains and spinal 
cords) were evaluated as follows: for each animal, each section was evaluated under 
20x or 40x optical fields (depending on the object of study) so as to cover the entire 
area of the section. Data were expressed per mm2 of tissue, where appropriate. Spinal 
cords had the majority of lesions (compared to brains), therefore pathological studies 
were focused on the spinal cord sections of the animals.  
 Depending on the evaluated parameter we used the following scales as 
previously described.39, 42 Axonal injury (AI), was evaluated using the following scale: 0 
= no AI, 1+ = scattered dystrophic injured axons without any spheroid or ovoid, 2+ = 
mild AI with the presence of at least one spheroid or ovoid, 3+ = moderate AI, 4+ = 
severe AI; generally injured axons were defined and identified as spheroids and ovoids 
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(which represent axonotmesis), and dilated (dystrophic) axons which represent injured 
axons not yet being cut. Axonal loss (AL) was evaluated using the following scale: 0 = 
normal axonal density, 1+ = <25 % AL, 2+ = mild AL (26-50 %), 3+ = moderate to 
severe (51-75 %) AL, 4+ = severe AL (>75 %); various degrees of decreased density of 
axons was attributed to axonal loss and evaluated accordingly. Tissue infiltrations were 
evaluated under a 20x objective and data were expressed as the number of infiltrating 
cells per mm2 and number of infiltrating cells per infiltration. The demyelination of white 
matter was evaluated under 40x optical fields: using a prefrontal grid, we measured the 
area of demyelination and the total area of white matter in each optical field and then 
calculated the % of demyelination.  
 
4.4. Statistical analysis 
  
 Statistical analysis of mouse data was performed using the SPSS 23.0 software. 
For scale clinical and histopathological data, normality of distribution was tested using 
Shapiro-Wilk tests. For 2 group comparisons we applied either Student's t-test 
(parametric data) or Mann-Whitney U test (non-parametric data). For nominal or ordinal 
data and comparisons between 2 groups we used Pearson chi-square or Fisher’s exact 
tests, where appropriate. Kaplan-Meier survival analysis was used for the clinical 
course of EAE, with “disease onset” as the end-point of the analysis (day of disease 
onset, dDO, was defined as the first day with clinical score of “1”). Mean Maximal Score 
(MMS) was calculated for each group using the maximal scores from each animal of 
each group. Disease burden was expressed as the Area Under the Curve (AUC), which 
was calculated for each mouse using the formula:43  
 
Data are expressed as mean±SEM, unless stated otherwise. 
 
4.5. Competition binding of linear and cyclic MOG35-55 to HLA-DR2 allele 
  
 Binding of l-MOG35-55 and c-MOG35-55 analogs to HLA-DR2 was performed as 
previously demonstrated.34, 35 Briefly, EBV transformed homozygous human B cell lines 
HTC-Lan (DRB1*1501, DRB5*0101) were used for isolating MHC class II molecule. 
HTC-Lan cell pellets were lyzed by nonidet P-40 and HLA-DR2 isolated from 
homogenates by affinity chromatography using the monoclonal antibody L243. The 
purity of the preparation was checked by SDS-PAGE, HPSEC and western blotting (not 
shown). Competition binding assays concerning linear MOG35-55 and c-MOG35-55 were 
carried out using Fluorescent AMCA-labelled allele-specific MBP83-99 for HLA-DR2b 
chain. Solubilized HLA-DR2 (0.66 mM) was incubated for 48 h at 37 oC with MBP83-99-
(AMCA)-labeled peptide dissolved in 150 mM sodium phosphate, pH 6.0, containing 15 
% acetonitrile, 0.1 % Zwittergent-12 (Calbiochem). Competition assays were performed 
in a 1 μM solution of AMCA peptide. All samples were analyzed on a Pharmacia 
Superdex 75 HR 5/20 high performance gel filtration column. The column was operated 
at a flow rate of 0.3 ml/min using the HPSEC buffer, pH 6.0. The eluent passed through 
a Shimadzu fluorescence spectrometer (350/450 nm) and a Merck ultraviolet detector 
(214 nm) set in series. Fluorescence and UV signals eluting with the HLA-DR dimers 
were recorded by a model D 2500 integrator (Merck-Hitachi). 
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4.6. Docking studies of the HLA complexes 
 
 The peptides were evaluated for their potential affinity using the consensus 
approach for prediction of peptide MHC class II binding affinity (CONSENSUS) on the 
Free epitope database and prediction resource (IEDB).  Peptides were evaluated in the 
IEDB analysis resource using the SMM-align,44 NN-align45 Sturniolo,46 and the 
Consensus47 algorithms. Using this procedure, for each peptide, a percentile rank for 
each of the three methods is generated by comparing the peptide's score against the 
scores of five million random 15-mers selected from SWISSPROT database. The 
MOG35-55 and MOG[45-55]-[35-44] (considering cyclization) peptides were evaluated for 
binding to allele H2-IAb using CLIP91-99 as control and to allele DRB1*1501 (HLA-DR2) 
using MBP82-99 as control. 
 
4.7. Model preparation of linear and cyclic MOG35-55 in complex with murine H2-IAb and 
human HLA-DR2. 
 
 Production of the model complexes was made by homology modeling using 
MODELLER 9.17,48 using the crystal structures of HLA-DR2b complexed with MBP83-96 
(pdb code 1BX2)37 and H2-IAb (pdb code 1MUJ)49 as templates. Linear MOG35-55 and c-
MOG35-55 (mouse, rat) peptides were aligned to the aforementioned crystalized peptides 
according to the docking results and positional restraints were applied to the protein. 
The overall stereochemical quality of the final models was evaluated by visual 
inspection and the discrete optimized energy (DOPE).50 Cyclization for MOG35-55 
peptides was performed manually by joining the C- and N- terminal residues, followed 
by an energy minimization of the whole complex by means of the conjugate gradient 
algorithm for 1000 steps in Discovery Studio v3.5.51 For the linear MOG35-55 complexes, 
the same energy minimization parameters were used.  
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